首页> 美国卫生研究院文献>Turkish Journal of Hematology >Physiopathology Etiologic Factors Diagnosis and Course of Polycythemia Vera as Related to Therapy According to William Dameshek 1940-1950
【2h】

Physiopathology Etiologic Factors Diagnosis and Course of Polycythemia Vera as Related to Therapy According to William Dameshek 1940-1950

机译:威廉·达米谢克(1940-1950)的生理病理学病因诊断和与治疗有关的真性红细胞增多症病程

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

According to Dameshek, true polycythemia (polycythemia vera: PV) is a chronic myeloproliferative disorder of the total bone marrow without any evidence of invasiveness, in which erythrocytosis, leukocytosis, and thrombocytosis are all simultaneously present. A possible hereditary or transmitted tendency may be present, but actual familial polycythemia is rare. As to the etiology, Dameshek proposed 2 highly speculative possibilities in 1950: the presence of excessive bone marrow stimulation by an unknown factor or factors, and a lack or a diminution in the normal inhibitory factor or factors. Dameshek’s hypothesis was confirmed in 2005 by Vainchenker in France by the discovery of the acquired JAK2V617F mutation as the cause of 3 phenotypes of classical myeloproliferative neoplasms: essential thrombocythemia, PV, and myelofibrosis. The JAK2V617F mutation induces a loss of inhibitory activity of the JH2 pseudokinase part on the JH1 kinase part of Janus kinase 2 (JAK2). This leads to enhanced activity of the normal JH1 kinase activity of JAK2, which makes the mutated hematopoietic stem cells hypersensitive to the hematopoietic growth factors thrombopoietin, erythropoietin, insulin-like growth factor-1, stem cell factor, and granulocyte colony-stimulating factor, resulting in trilinear myeloproliferation. In retrospect, the situation observed by Dameshek where all “stops” to blood production in the bone marrow are pulled in PV is caused by the JAK2V617F mutation.Dameshek considered PV patients as fundamentally normal and therefore the treatment should be as physiologic as possible. For this reason, a systematic phlebotomy/iron deficiency method of treatment was recommended; the use of radioactive phosphorus is reserved for refractory cases and cases of major thrombosis. If the patient lives long enough and does not succumb to the effects of thrombosis or other complications, the marrow will gradually show signs of diminished activity. The blood smear shows nucleated red cells, increased polychromatophilia, and immature granulocytes of various types. With increasing reduction of erythropoietic tissue, myelofibrosis becomes more of an organized mass of fibrous tissue. There is prominent extramedullary hematopoiesis in the spleen, which becomes extraordinarily large and in some cases occupies almost the entire abdominal cavity. The enlarged spleen is made up largely of metaplastic marrow tissue in primary myeloid metaplasia of the spleen.>Conflict of interest:None declared.
机译:根据Dameshek所说,真正的红细胞增多症(真性红细胞增多症:PV)是一种总骨髓的慢性骨髓增生性疾病,没有任何侵袭性证据,其中红细胞增多症,白细胞增多症和血小板增多症同时存在。可能存在遗传或传播的趋势,但实际的家族性红细胞增多症很少。关于病因,Dameshek在1950年提出了2种高度投机的可能性:一种或多种未知因素对骨髓的过度刺激,以及正常或多种抑制因子的缺乏或减少。 Dameshek的假设在2005年由法国的Vainchenker证实,该发现是由于获得性JAK2V617F突变而引起的,该突变是三种经典骨髓增生性肿瘤的表型:原发性血小板增多症,PV和骨髓纤维化。 JAK2V617F突变导致Janus激酶2(JAK2)的JH1激酶部分失去JH2假激酶部分的抑制活性。这会导致JAK2的正常JH1激酶活性增强,从而使突变的造血干细胞对造血生长因子血小板生成素,促红细胞生成素,胰岛素样生长因子-1,干细胞因子和粒细胞集落刺激因子高度敏感,导致三线性骨髓增生。回顾过去,Dameshek观察到的情况是,JAK2V617F突变导致了所有“停止”骨髓造血的PV停止。Dameshek认为PV患者从根本上是正常的,因此治疗应尽可能采用生理方法。因此,建议采用系统的放血/铁缺乏症治疗方法。放射性磷的使用仅限于难治性病例和严重血栓形成病例。如果患者的寿命足够长,并且不屈服于血栓形成或其他并发症,骨髓将逐渐显示出活动减弱的迹象。血液涂片显示有核红细胞,多色性增加和各种类型的未成熟粒细胞。随着红细胞生成组织减少的增加,骨髓纤维化更多地是有组织的纤维组织块。脾脏中存在突出的髓外造血,其异常大,在某些情况下几乎占据整个腹腔。脾脏肿大主要由脾的原发性髓质化生中的化生性骨髓组织组成。>利益冲突:未宣布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号